Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke?
Jonas
S
S
Department of Neurology, New York University School of Medicine, New York 10016, USA.
Tran
A Q
AQ
Eisenberg
E
E
Azam
M
M
Viera
D
D
Grumet
S
S
D000818:Animals; D002544:Cerebral Infarction / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000628:therapy*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005677:G(M1) Ganglioside / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006438:Hemodilution; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009553:Nimodipine / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D005938:Glucocorticoids; D018696:Neuroprotective Agents; D005677:G(M1) Ganglioside; D009553:Nimodipine; D010959:Tissue Plasminogen Activator